ADVM-043 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 231 | Alpha-1-antitrypsin deficiency | 1 |
231. Alpha-1-antitrypsin deficiency
Clinical trials : 93 / Drugs : 77 - (DrugBank : 8) / Drug target genes : 10 - Drug target pathways : 36
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03804021 (ClinicalTrials.gov) | January 11, 2019 | 11/1/2019 | Long-Term Follow-up Study of ADVM-043 | Post-treatment Long-term Follow-up Study of ADVM-043 Gene Therapy in Alpha-1 Antitrypsin Deficiency | Alpha-1 Antitrypsin Deficiency | Genetic: ADVM-043 | Adverum Biotechnologies, Inc. | NULL | Enrolling by invitation | 18 Years | N/A | All | 6 | United States |